International journal of clinical oncology · 2026
Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jo Ami, Shoji Tadahiro, Kitamura Ayaka, Musashi Miku, Tatsuki Shunsuke, Jonai Nanako, Chiba Yohei, Sato Sho, Takatori Eriko, Kaido Yoshitaka, Nagasawa Takayuki, Kagabu Masahiro, Takahashi Fumiaki, Aida Takeshi, Baba Tsukasa
Аннотация
BACKGROUND: Although poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) rechallenge has been explored for platinum-sensitive recurrent ovarian cancer, data in Japanese patients remain scarce. This retrospective study evaluated the safety and efficacy of PARPi rechallenge in this population.
PATIENTS AND METHODS: Twenty-eight Japanese patients with ovarian cancer who experienced platinum-sensitive recurrence during or after PARPi therapy and subsequently responded to platinum-based chemotherapy were included. Olaparib and niraparib were administered as PARPi rechallenge in 19 and 9 patients, respectively. The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS) and adverse events (AEs).
RESULTS: The median follow-up period was 19 months (range, 3-47). Median PFS and OS in the overall population were 6 months (95% CI, 3-8) and 32 months (95% CI, 28-not reached), respectively. The median PFS for patients who had received two prior regimens was 6 months, compared with 5 months for those who had received three or more regimens, with no significant difference (P = 0.734). Grade ≥3 hematologic toxicities included neutropenia (n = 4), anemia (n = 7), and thrombocytopenia (n = 2). Non-hematologic toxicities included interstitial pneumonia, hypertension, and proteinuria, with one case each. No treatment-related deaths occurred.
CONCLUSIONS: PARPi rechallenge in Japanese patients with platinum-sensitive recurrent ovarian cancer demonstrated a manageable safety profile but limited efficacy. Larger, prospective studies incorporating molecular stratification are required to better define the clinical role of PARPi rechallenge.
PATIENTS AND METHODS: Twenty-eight Japanese patients with ovarian cancer who experienced platinum-sensitive recurrence during or after PARPi therapy and subsequently responded to platinum-based chemotherapy were included. Olaparib and niraparib were administered as PARPi rechallenge in 19 and 9 patients, respectively. The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS) and adverse events (AEs).
RESULTS: The median follow-up period was 19 months (range, 3-47). Median PFS and OS in the overall population were 6 months (95% CI, 3-8) and 32 months (95% CI, 28-not reached), respectively. The median PFS for patients who had received two prior regimens was 6 months, compared with 5 months for those who had received three or more regimens, with no significant difference (P = 0.734). Grade ≥3 hematologic toxicities included neutropenia (n = 4), anemia (n = 7), and thrombocytopenia (n = 2). Non-hematologic toxicities included interstitial pneumonia, hypertension, and proteinuria, with one case each. No treatment-related deaths occurred.
CONCLUSIONS: PARPi rechallenge in Japanese patients with platinum-sensitive recurrent ovarian cancer demonstrated a manageable safety profile but limited efficacy. Larger, prospective studies incorporating molecular stratification are required to better define the clinical role of PARPi rechallenge.